Repligen Corporation (NASDAQ:RGEN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Repligen Corporation (NASDAQ:RGEN) has been assigned an average rating of “Moderate Buy” from the thirteen analysts that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $177.9167.

A number of research firms have recently weighed in on RGEN. Weiss Ratings downgraded shares of Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, January 30th. Wells Fargo & Company upped their price objective on Repligen from $175.00 to $190.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Canaccord Genuity Group increased their price objective on Repligen from $150.00 to $165.00 and gave the company a “hold” rating in a report on Wednesday, October 29th. UBS Group boosted their target price on Repligen from $190.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Finally, Wall Street Zen raised Repligen from a “hold” rating to a “buy” rating in a research report on Saturday, February 7th.

Repligen Price Performance

RGEN opened at $136.44 on Monday. Repligen has a fifty-two week low of $102.96 and a fifty-two week high of $175.77. The firm has a 50-day moving average of $159.23 and a 200 day moving average of $145.84. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.14 and a current ratio of 8.36. The firm has a market cap of $7.68 billion, a P/E ratio of 6,825.41, a PEG ratio of 2.49 and a beta of 1.13.

Insider Activity

In other news, Director Karen A. Dawes sold 275 shares of Repligen stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total value of $44,275.00. Following the completion of the transaction, the director owned 91,821 shares in the company, valued at $14,783,181. This trade represents a 0.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO James Bylund sold 2,191 shares of the business’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $151.21, for a total transaction of $331,301.11. Following the completion of the sale, the chief operating officer directly owned 21,520 shares in the company, valued at approximately $3,254,039.20. This trade represents a 9.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 4,657 shares of company stock worth $706,877. Insiders own 1.20% of the company’s stock.

Hedge Funds Weigh In On Repligen

Several hedge funds have recently made changes to their positions in RGEN. AQR Capital Management LLC purchased a new stake in Repligen during the 1st quarter worth about $262,000. Jones Financial Companies Lllp increased its position in shares of Repligen by 3,850.6% during the first quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock valued at $814,000 after buying an additional 6,238 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Repligen by 16.8% during the first quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock valued at $18,067,000 after buying an additional 20,375 shares during the period. TD Asset Management Inc lifted its holdings in shares of Repligen by 54.8% in the second quarter. TD Asset Management Inc now owns 79,224 shares of the biotechnology company’s stock worth $9,854,000 after buying an additional 28,052 shares in the last quarter. Finally, Angeles Wealth Management LLC bought a new position in shares of Repligen in the second quarter valued at approximately $209,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.